ARTICLE | Clinical News
Novartis first partner in RWE collaboration for dermatology
February 27, 2019 6:29 PM UTC
PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program.
TARGET-DERM will gather real world, de-identified patient-level data from electronic medical records as well as claims data, starting with atopic dermatitis and eventually adding other immune-mediated inflammatory skin conditions...